Evidence map›Paper›PMID 33865832›Full record

ArticleBiochemical pharmacology2021

RNA therapeutics: From biochemical pharmacology to technology development and clinical applications.

Baitang Ning, Ai-Ming Yu

Abstract readEditorialComment
In one paragraph

Article in Biochemical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. The Growing Class of Novel RNAi Therapeutics.Molecular pharmacology · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Baitang NingNational Center for Toxicological Research, US Food and Drug Administration (NCTR), 3900 NCTR Road, HFT100, Jefferson, AR 72079, United States. Electronic address: baitang.ning@fda.hhs.gov.
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, 2700 Stockton Blvd, Suite 2130, Sacramento, CA 95817, United States. Electronic address: aimyu@ucdavis.edu.

Funding

Novel bioengineered microRNA therapeutics for lung cancerR01CA225958 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2019 to 2026
$3.7M
Recombinant microRNAs in xenobiotic and nutrient dispositionR01CA253230 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Meijuan Tu · 2021 to 2026
$1.7M
NCI NIH HHS R01 CA225958NCI NIH HHS R01 CA253230
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Industrial DevelopmentRNARNA

Identifiers

PMID33865832
PMCPMC9514225

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.